Australia markets close in 3 hours 5 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.97+0.25 (+3.24%)
At close: 04:00PM EST
8.11 +0.14 (+1.76%)
After hours: 07:36PM EST

Allogene Therapeutics, Inc.

210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700

Full-time employees356

Key executives

NameTitlePayExercisedYear born
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.Co-Founder & Exec. Chairman726.91kN/A1949
Dr. David D. Chang M.D., Ph.D.Co-Founder, Pres, CEO & Director1.09M190.77k1960
Mr. Joshua A. KazamCo-Founder & Director657.16kN/A1977
Dr. Eric Thomas Schmidt Ph.D.Chief Financial Officer655.5k103.68k1970
Dr. Alison Moore Ph.D.Chief Technical Officer743.55kN/A1967
Mr. Veer BhavnagriGen. Counsel & Compliance Officer653.37k1.34M1983
Ms. Barbra SasuChief Scientific OfficerN/AN/AN/A
Mr. Stephen ChengChief Information OfficerN/AN/AN/A
Ms. Christine CassianoChief Communications OfficerN/AN/AN/A
Ms. Susan R. LundeenChief People OfficerN/AN/A1966
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate governance

Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 28 January 2023 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.